Acquiring orphans

Nature Biotechnology

Volumn 32, Issue 3, 2014, Pages 213-216

  Rooswinkel, Rogier ^a   Mulder, Geert Jan ^a   Van Deventer, Sander ^a,b  

^a Forbion Capital Partners   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ERYTHROPOIETIN; OBATOCLAX; ORPHAN DRUG; RITUXIMAB; TAFAMIDIS; TANESPIMYCIN;

ARTICLE; CLINICAL PROTOCOL; DRUG APPROVAL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; EUROPE; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; INVESTMENT; MERGERS AND ACQUISITIONS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PURCHASING; RARE DISEASE; UNITED STATES; DRUG MANUFACTURE;

DRUG INDUSTRY; ORPHAN DRUG PRODUCTION;

EID: 84898664863     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2836     Document Type: Article

References (8)

1. Meekings, K.N., Williams, C.S. & Arrowsmith, J.E. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov. Today 17, 660-664 (2012).
2. Sasinowski, F.J. Quantum of effectiveness evidence in FDA's approval of orphan drugs. Drug Inf. J. 46, 238-263 (2012).
3. Mullard, A. 2012 FDA drug approvals. Nat. Rev. Drug Discov. 12, 87-90 (2013).
4. N ovartis Institutes for BioMedical Research. Proofof-concept: innovation in Novartis R&D Novartis Institutes for BioMedical Research http://www. nibr.com/cs/groups/public/@nibr-com/documents/document/n-prod-200338.pdf (March 2009).
5. Wellman-Labadie, O. & Zhou, Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95, 216-228 (2010).
6. G iniatullina, A., Boorsma, M., Mulder, G.-J. & van Deventer, S. Building for big pharma. Nat. Biotechnol. 31, 284-287 (2013).
7. O'Sullivan, B.P., Orenstein, D.M. & Milla, C.E. Pricing for orphan drugs: will the market bear what society cannot? JAMA 310, 1343-1344 (2013).
8. HBM Partners. HBM Pharma/Biotech M&A Report 2012. HBM Partners http://www.hbmpartners.com/wAssets/docs/industry-reports/HBM-Pharma-Biotech-M-A- Report-2012.pdf (January 2013).